权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

(PQ#9) Promoting Axon Stability to Prevent Therapy-induced Peripheral Neuropathy

（PQ

基本信息

批准号：
9978739
负责人：
Aaron Diantonio
金额：
$ 46.54万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-16 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9978739
关键词：
Ablation Address Aftercare Axon B-Cell Lymphomas Biological Assay Cancer Survivor Chemotherapy-Oncologic Procedure Cleaved cell Clinical Defect Development Dose-Limiting Effectiveness Enzymes Funding Opportunities Genetic Growth Health Interneurons Knockout Mice Lymphoma cell Malignant Neoplasms Metabolic Methods Modeling Molecular Mus NAD+ Nucleosidase Neural Conduction Neuropathy Numbness Pathway interactions Patients Peripheral Nervous System Diseases Pharmaceutical Preparations Prevention Prevention strategy Prevention therapy Proteins Quality of life Regimen Research Symptoms Testing Vincristine Withholding Treatment axon injury axonal degeneration cancer cell cancer therapy chemotherapy design dosage effective therapy in vivo in vivo bioluminescence imaging insight knock-down mouse model novel novel therapeutics pain sensitivity painful neuropathy prevent programs response sensory neuropathy side effect therapeutic candidate therapy development treatment response treatment strategy tumor tumor growth

项目摘要

Project Summary/Abstract: Therapy-induced peripheral neuropathy (TIPN) is a very common and often dose-limiting side effect of anti-cancer therapy. Clinically, TIPN is a predominantly sensory peripheral neuropathy characterized by numbness, tingling, and often, neuropathic pain. These symptoms can persist for years after cessation of treatment, and so TIPN can significantly diminish patient's quality-of-life both during and after treatment. Moreover, the development of TIPN often necessitates reducing drug dosage or switching regimens, and therefore limits the effectiveness of anti-cancer therapy. Currently, there are no effective treatments for TIPN. Axon loss is a hallmark of this neuropathy, suggesting that mechanistically distinct chemotherapeutics may feed into a common axonal degeneration program. We have demonstrated that genetic inhibition of SARM1, the central executioner of this core axonal degeneration program, blocks the development of TIPN in a mouse model of vincristine-induced peripheral neuropathy. The SARM1 pathway induces axon loss by triggering depletion of the essential metabolic co-factor NAD. Here we seek to block the development of TIPN by countering this loss of NAD in order to maintain axonal health. We also explore mechanisms to block the activation of SARM1 as novel therapeutic strategies for blocking the development of TIPN. Finally, targeting the SARM1 pathway will be a useful treatment for TIPN if manipulating this pathway does not affect tumor growth or chemotherapeutic efficacy. We will explore this using genetic tumor models. If successful, this project will identify novel treatment strategies for the prevention of TIPN.

项目摘要/摘要：治疗诱发的周围神经病(TIPN)是一种非常常见的副作用，通常是剂量有限的抗癌治疗。临床上，TIPN是一种主要的感觉性周围神经病，其特征是麻木、刺痛，通常还有神经病理性疼痛。这些症状在停止后可持续数年。因此，TIPN在治疗期间和治疗后都会显著降低患者的生活质量。此外，TIPN的发展往往需要减少药物剂量或改变方案，以及因此限制了抗癌治疗的有效性。目前，还没有有效的治疗TIPN的方法。轴突丢失是这种神经病变的一个标志，这表明机械上不同的化疗药物可能输入一个共同的轴突变性程序。我们已经证明了SARM1的遗传抑制，这个核心轴突变性程序的中央执行者阻止了小鼠TIPN的发展长春新碱诱导的周围神经病模型。Sarm1通路通过触发诱导轴突丢失基本代谢辅助因子NAD的耗尽。在这里，我们试图通过以下方式阻止TIPN的发展对抗这种NAD的损失，以维持轴突健康。我们还探索了阻止激活Sarm1作为阻断TIPN发展的新治疗策略。最后，目标明确如果操纵Sarm1通路不影响肿瘤，Sarm1通路将是治疗TIPN的有效途径生长或化疗效果。我们将使用基因肿瘤模型来探索这一点。如果成功，这将是该项目将确定预防TIPN的新治疗策略。